MRM
MEDIROM Healthcare Technologies Inc.
Personal Products & Services
Market Cap$6M
5Y Perf.-91.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MRM vs ACMR
Revenue, margins, valuation, and 5-year total return — side by side.
ACMR
ACM Research, Inc.
Semiconductors
Market Cap$3.92B
5Y Perf.+118.6%
MRM vs ACMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MRM | ACMR |
|---|---|---|
| Industry | Personal Products & Services | Semiconductors |
| Market Cap | $6M | $3.92B |
| Revenue (TTM) | $11.91B | $901M |
| Net Income (TTM) | $615M | $94M |
| Gross Margin | 26.4% | 44.4% |
| Operating Margin | -0.9% | 12.1% |
| Forward P/E | 6.4x | 29.7x |
| Total Debt | $3.96B | $303M |
| Cash & Equiv. | $329M | $766M |
MRM vs ACMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MRM
ACMR
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| MEDIROM Healthcare … (MRM) | 100 | 8.1 | -91.9% |
| ACM Research, Inc. (ACMR) | 100 | 218.6 | +118.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MRM vs ACMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACMR leads in 4 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. MEDIROM Healthcare Technologies Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
MRM
MEDIROM Healthcare Technologies Inc.
The Growth Play
MRM is the clearest fit if your priority is growth exposure and valuation efficiency.
- Rev growth 21.5%, EPS growth 28.1%, 3Y rev CAGR 15.3%
- PEG 0.13 vs ACMR's 0.84
- 21.5% revenue growth vs ACMR's 15.2%
Best for: growth exposure and valuation efficiency
ACMR
ACM Research, Inc.
The Long-Run Compounder
ACMR carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 30.7% 10Y total return vs MRM's -92.3%
- Lower volatility, beta 3.24, Low D/E 15.7%, current ratio 3.27x
- Beta 3.24, yield 0.2%, current ratio 3.27x
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MRM | 21.5% revenue growth vs ACMR's 15.2% |
| Value | MRM | Lower P/E (6.4x vs 29.7x), PEG 0.13 vs 0.84 |
| Quality / Margins | ACMR | 10.4% margin vs MRM's 5.2% |
| Stability / Safety | ACMR | Lower D/E ratio (15.7% vs 333.1%) |
| Dividends | ACMR | 0.2% yield; 3-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | ACMR | +195.6% vs MRM's +47.9% |
| Efficiency (ROA) | MRM | 11.8% ROA vs ACMR's 3.9%, ROIC -0.3% vs 7.0% |
MRM vs ACMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
MRM vs ACMR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACMRLAGGINGMRM
MRMMEDIROM Healthcare Te…
1leads
ACMRACM Research, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs MRMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACMR5/6
Valuation MetricsMultiples, price ratios, and targets
MRM5/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACMR6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ACMR6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACMR leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MRM is the larger business by revenue, generating $11.9B annually — 13.2x ACMR's $901M. ACMR is the more profitable business, keeping 10.4% of every revenue dollar as net income compared to MRM's 5.2%. On growth, ACMR holds the edge at +9.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MRMMEDIROM Healthcar… | ACMRACM Research, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $11.9B | $901M |
| EBITDAEarnings before interest/tax | $338M | $126M |
| Net IncomeAfter-tax profit | $615M | $94M |
| Free Cash FlowCash after capex | -$2.0B | -$69M |
| Gross MarginGross profit ÷ Revenue | +26.4% | +44.4% |
| Operating MarginEBIT ÷ Revenue | -0.9% | +12.1% |
| Net MarginNet income ÷ Revenue | +5.2% | +10.4% |
| FCF MarginFCF ÷ Revenue | -16.8% | -7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -99.4% | +9.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +99.5% | -76.1% |
ACMR leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
MRM leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
At 6.4x trailing earnings, MRM trades at a 85% valuation discount to ACMR's 43.2x P/E. Adjusting for growth (PEG ratio), MRM offers better value at 0.13x vs ACMR's 1.22x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | MRMMEDIROM Healthcar… | ACMRACM Research, Inc. |
|---|---|---|
| Market CapShares × price | $6M | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $29M | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | 6.36x | 43.21x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 29.68x |
| PEG RatioP/E ÷ EPS growth rate | 0.13x | 1.22x |
| EV / EBITDAEnterprise value multiple | 16.75x | 27.49x |
| Price / SalesMarket cap ÷ Revenue | 0.11x | 4.35x |
| Price / BookPrice ÷ Book value/share | 0.89x | 2.06x |
| Price / FCFMarket cap ÷ FCF | — | — |
MRM leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
ACMR leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MRM delivers a 2.4% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $6 for ACMR. ACMR carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to MRM's 3.33x. On the Piotroski fundamental quality scale (0–9), MRM scores 6/9 vs ACMR's 2/9, reflecting solid financial health.
| Metric | MRMMEDIROM Healthcar… | ACMRACM Research, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +2.4% | +6.1% |
| ROA (TTM)Return on assets | +11.8% | +3.9% |
| ROICReturn on invested capital | -0.3% | +7.0% |
| ROCEReturn on capital employed | -0.5% | +6.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 2 |
| Debt / EquityFinancial leverage | 3.33x | 0.16x |
| Net DebtTotal debt minus cash | $3.6B | -$463M |
| Cash & Equiv.Liquid assets | $329M | $766M |
| Total DebtShort + long-term debt | $4.0B | $303M |
| Interest CoverageEBIT ÷ Interest expense | 0.56x | 20.44x |
ACMR leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ACMR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACMR five years ago would be worth $23,344 today (with dividends reinvested), compared to $1,176 for MRM. Over the past 12 months, ACMR leads with a +195.6% total return vs MRM's +47.9%. The 3-year compound annual growth rate (CAGR) favors ACMR at 80.5% vs MRM's -41.5% — a key indicator of consistent wealth creation.
| Metric | MRMMEDIROM Healthcar… | ACMRACM Research, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -40.8% | +31.9% |
| 1-Year ReturnPast 12 months | +47.9% | +195.6% |
| 3-Year ReturnCumulative with dividends | -80.0% | +487.9% |
| 5-Year ReturnCumulative with dividends | -88.2% | +133.4% |
| 10-Year ReturnCumulative with dividends | -92.3% | +3065.8% |
| CAGR (3Y)Annualised 3-year return | -41.5% | +80.5% |
ACMR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MRM and ACMR each lead in 1 of 2 comparable metrics.
Risk & Volatility
MRM is the less volatile stock with a -0.54 beta — it tends to amplify market swings less than ACMR's 3.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACMR currently trades 82.6% from its 52-week high vs MRM's 26.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MRMMEDIROM Healthcar… | ACMRACM Research, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.54x | 3.24x |
| 52-Week HighHighest price in past year | $4.45 | $71.65 |
| 52-Week LowLowest price in past year | $0.72 | $19.26 |
| % of 52W HighCurrent price vs 52-week peak | +26.1% | +82.6% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 60.7 |
| Avg Volume (50D)Average daily shares traded | 378K | 1.2M |
Evenly matched — MRM and ACMR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
ACMR is the only dividend payer here at 0.19% yield — a key consideration for income-focused portfolios.
| Metric | MRMMEDIROM Healthcar… | ACMRACM Research, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $40.00 |
| # AnalystsCovering analysts | — | 10 |
| Dividend YieldAnnual dividend ÷ price | — | +0.2% |
| Dividend StreakConsecutive years of raises | — | 3 |
| Dividend / ShareAnnual DPS | — | $0.11 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACMR leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MRM leads in 1 (Valuation Metrics). 1 tied.
Best OverallACM Research, Inc. (ACMR)Leads 3 of 6 categories
Loading custom metrics...
MRM vs ACMR: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is MRM or ACMR a better buy right now?
For growth investors, MEDIROM Healthcare Technologies Inc.
(MRM) is the stronger pick with 21. 5% revenue growth year-over-year, versus 15. 2% for ACM Research, Inc. (ACMR). MEDIROM Healthcare Technologies Inc. (MRM) offers the better valuation at 6. 4x trailing P/E, making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MRM or ACMR?
On trailing P/E, MEDIROM Healthcare Technologies Inc.
(MRM) is the cheapest at 6. 4x versus ACM Research, Inc. at 43. 2x.
03Which is the better long-term investment — MRM or ACMR?
Over the past 5 years, ACM Research, Inc.
(ACMR) delivered a total return of +133. 4%, compared to -88. 2% for MEDIROM Healthcare Technologies Inc. (MRM). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus MRM's -92. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MRM or ACMR?
By beta (market sensitivity over 5 years), MEDIROM Healthcare Technologies Inc.
(MRM) is the lower-risk stock at -0. 54β versus ACM Research, Inc. 's 3. 24β — meaning ACMR is approximately -695% more volatile than MRM relative to the S&P 500. On balance sheet safety, ACM Research, Inc. (ACMR) carries a lower debt/equity ratio of 16% versus 3% for MEDIROM Healthcare Technologies Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MRM or ACMR?
By revenue growth (latest reported year), MEDIROM Healthcare Technologies Inc.
(MRM) is pulling ahead at 21. 5% versus 15. 2% for ACM Research, Inc. (ACMR). On earnings-per-share growth, the picture is similar: MEDIROM Healthcare Technologies Inc. grew EPS 28. 1% year-over-year, compared to -10. 5% for ACM Research, Inc.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MRM or ACMR?
ACM Research, Inc.
(ACMR) is the more profitable company, earning 10. 4% net margin versus 1. 8% for MEDIROM Healthcare Technologies Inc. — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -0. 2% for MRM. At the gross margin level — before operating expenses — ACMR leads at 44. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — MRM or ACMR?
In this comparison, ACMR (0.
2% yield) pays a dividend. MRM does not pay a meaningful dividend and should not be held primarily for income.
08Is MRM or ACMR better for a retirement portfolio?
For long-horizon retirement investors, MEDIROM Healthcare Technologies Inc.
(MRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 54)). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRM: -92. 3%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between MRM and ACMR?
These companies operate in different sectors (MRM (Consumer Cyclical) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(MRM: -99.4% · ACMR: 9.4%)Net Margin>
%
(MRM: 5.2% · ACMR: 10.4%)P/E Ratio<
x
(MRM: 6.4x · ACMR: 43.2x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.